Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

279 results about "Stomach mucosa" patented technology

Metformin hydrochloride enteric-coated sustained release tablet and preparation method thereof

The invention discloses a metformin hydrochloride enteric-coated sustained release tablet which is prepared by enteric coating the metformin hydrochloride sustained release tablet. Compared with the prior art, the sustained release tablet integrates with the enteric coating technology to prepare a new form of the metformin hydrochloride enteric-coated sustained release tablet. By using the enteric coating technology, the metformin hydrochloride does not disintegrate in the stomach or stimulate the gastric mucosa, and the adverse reaction of nausea, stomachache and diarrhea caused by medicine taking can be avoided; meanwhile, the metformin hydrochloride is prevented from being damaged by gastric juice, and the bioavailability is improved. The product is a sustained release preparation, the medicine can stably release in vivo, the effective blood concentration can be maintained for a long time, the toxic and side effects caused by over-high blood concentration in a short time are avoided, the medicine taking frequency is decreased, and the patient compliance is improved as well.
Owner:贵州天安药业股份有限公司

Combination tablet with chewable outer layer

ActiveUS20100166810A1Diminishing prostaglandin-mediated flush side effectIncrease in IR levelBiocideAnimal repellantsOral mucosaDosing regimen
A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.
Owner:VITALS

Aloe bird nest drink food and preparation method thereof

InactiveCN101574165ARefreshing and smooth tasteInvigorate the spleen and moisten the lungsFood preparationFood technologyBird nest
The invention belongs to the technical field of drink foods, and in particular relates to an aloe bird nest drink food and a preparation method thereof. The aloe bird nest drink food comprises the following raw materials e by weight percentage: 0.05 to 40 percent of aloe, 0.005 to 0.2 percent of bird nest (in terms of dry basis), 1 to 50 percent of edulcorant, 0 to 20 percent of fruit and vegetable juice, 0 to 0.5 percent of acid taste additive and acid taste regulator, 0 to 6 percent of gelata, and 40 to 85 percent of water. The aloe bird nest drink food integrates the efficacy characteristics of the aloe and the bird nest, not only has fresh and lubricous mouthfeel, but also has the health care functions of invigorating the spleen and moistening the lung, protecting gastric mucosa, resisting inflammation and sterilizing, strengthening the immune system, resisting radiation, hairdressing and the like.
Owner:东莞市德亨饮料食品有限公司

Lactobacillus acidophilus LA-10A capable of inhibiting helicobacter pylori and application thereof

ActiveCN111118106AReduce or prevent infectionInhibit or eliminate colonizationAntibacterial agentsMilk preparationBiotechnologyMetabolite
The invention provides a method of screening a bacterial strain capable of inhibiting helicobacter pylori. The method includes a way that qualitative and quantitative assessment can be directly conducted on screened bacterial strains if the screened bacterial strains can inhibit or eliminate the colonization of the helicobacter pylori on gastric mucosal cells by utilizing DNA fluorescent labels and flow cytometry. According to the invention, the following points are considered when conducting screening model tests in vitro: (1) viability in an extremely acidic stomach environment; (2) inhibition ability of the bacterial strains itself or metabolites of the bacterial strains to HP reproduction in vitro; and (3) ability of inhibiting or relieving the colonization of the helicobacter pylori strains on gastric mucosa. According to the invention, developing the method of directly assessing in vitro if the HP colonization can be inhibited is of great significance to the practical applicationof the bacterial strain provided by the invention. According to the invention, lactobacillus acidophilus LA-10A capable of inhibiting the helicobacter pylori is screened out. According to a test, thelactobacillus acidophilus LA-10A can relieve or prevent the helicobacter pylori infection. The lactobacillus acidophilus LA-10A can be used to prepare functional food or pharmaceutical compositions.
Owner:THANKCOME BIOLOGICAL SCI & TECH CO LTD

Camellia effective ingredients and extracting method and use thereof

InactiveCN101301401AClear compositionMulti-target synergy Toxic and side effectsMetabolism disorderDigestive systemChemistryCamellia sinensis
The invention provides an extracting method, comprising a water extraction method, an alcohol extraction, a macroporous resin purification method and a solvent extraction method. By adopting the method, the contents of main effective constituents of the obtained extractive are: 1 to 25 percent of TFA, 1 to 20 percent of total Saponins and 1 to 3 percent of phenethyl alcohol glycoside. The invention also provides a method for making the appropriate preparation formulation by using the camellia directly or mixing the solid or liquid of the preparation and the like pharmaceutically in general. The effective constituents of the camellia and the preparation thereof have the functions of reducing blood sugar and lipid and protecting the gastric mucosa, etc. The extracting method has simple implementation and low cost, extracts sufficiently and is suitable for the industrial production; and the extractive has evident activity, precise healing effect and does not have the toxic and side effect.
Owner:SHENYANG PHARMA UNIVERSITY

Dendrobium officinale and hericium erinaceus compound chewable tablet and preparation method thereof

ActiveCN103463457ASolve the problem that the drug effect can not fully workFully absorbedAntibacterial agentsAntipyreticCelluloseMethyl cellulose
The invention discloses a dendrobium officinale and hericium erinaceus compound chewable tablet. According to a formula, the dendrobium officinale and hericium erinaceus compound chewable tablet comprises 2 to 10 parts of dendrobium officinale, 10 to 30 parts of hericium erinaceus, 10 to 70 parts of Guangxi dioscorea opposita thunb, 3 to 5 parts of corrective agent, 20 to 30 parts of hydroxypropyl methyl cellulose, 5 to 15 parts of maltodextrin, and 1 to 3 parts of lubricant. The preparation method comprises the following steps: respectively crushing all the raw materials; screening with 500 meshes to obtain submicron powder; combining in proportion as indicated in the formula; uniformly agitating; adding ethyl alcohol to granulate in a wet manner; drying at a temperature of 60 to 80 DEG C until the moisture content is up to 4 to 5% in percentage by weight; cooling to reach room temperature; screening with 60 meshes; adding the lubricant to mix; then performing to obtain the dendrobium officinale and hericium erinaceus compound chewable tablet. The chewable tablet has the health care effects of clearing heat and promoting fluid, protecting gastric mucosa, nourishing both stomach and liver, diminishing inflammation and relieving pain, replenishing Qi and tonifying lung, and regulating lung and reducing phlegm.
Owner:AGRI PROD PROCESSING INST GUANGXI ACADEMY OF AGRI SCI +1

Metformin hydrochloride sustained-release capsule and its preparation method

The invention relates to a metformin hydrochloride sustained-release capsule and its preparation method. The metformin hydrochloride sustained-release capsule is prepared by steps of coating a metformin hydrochloride granule sustained-release material and putting into an enteric capsule. In comparison with the prior art, sustained-release granules and enteric capsule filling technology are combined together to prepare the new dosage form of metformin hydrochloride sustained-release (enteric-coated) capsule. As the sustained-release granule coating and enteric capsule filing technology is adopted, metformin hydrochloride will not be disintegrated and will not stimulates gastric mucosa, and adverse reactions such as nausea, stomachache, diarrhoea and the like caused by medication can be avoided. Meanwhile, metformin hydrochloride will not be damaged by gastric juice, and bioavailability of metformin hydrochloride is raised. In addition, the product provided by the invention is also a sustained-release enteric-coated preparation. The medicine can be stably released in a body, effective plasma concentration is maintained for a long time, and toxic and side effect which might be caused by higher plasma concentration within a short time are avoided. The frequency for taking the medicine is reduced, and patient compliance is also raised.
Owner:BOSEN BIO PHARMA SHANXI PROVINCE

Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof

The invention relates to the pharmaceutical preparation field and in particular to a sodium dichlorophenolate micro-pill pharmaceutical preparation and a preparation method thereof. The micro-pill pharmaceutical preparation is prepared by micro-pills, which is characterized in that the micro-pill is of enteric slow-release micro-pill, the micro-pill consists of a hollow pill core, an active layer and an outer layer lagging cover, the active layer comprises sodium dichlorophenolate, a binding-property slow-release material and a binding-property enteric material, and the outer layer comprises a slow-release material. With the particular process and formula, a release system thereof is made into a unique double slow-release system, i.e. a skeleton-type scattering system is combined with a multi-layer semi-penetration film lagging cover system, so the main medicine can be continuously and stably released in the complicated internal environment of the human body. In addition, by adopting unique auxiliary materials, the micro-pill is free from being dissolved in the stomach and almost has no harm on the gastric mucosa, the medicine is ensured to have continuous effect of 24 hours inside the intestinal tract, the bioavailability is improved, and the application effect of the medicine is ensured.
Owner:HANGZHOU SHARPLY PHARM R&D INSTIT +1

Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide

Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. Pylori in a subject infected by H. Pylori, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Owner:RHODE ISLAND HOSPITAL

Oral liquid for treating chronic atrophic gastritis

The invention belongs to the technical field of traditional Chinese medicines and relates to oral liquid for treating chronic atrophic gastritis. The oral liquid is prepared by the following components in parts by weight: 10 parts of Zhejiang white atractylodes rhizome, 15 parts of poria cocos, 10 parts of orange peel, 10 parts of pinellia tenata breit, 10 parts of vinegar rhizoma cyperi, 10 parts of fructus amomi, 10 parts of mangnolia officinalis, 10 parts of vinegar curcuma aromatic, 15 parts of artemisia anomala, 6 parts of cassia twig, 10 parts of rhizoma corydalis, 10 parts of hawthorn, 10 parts of roasted malt, 10 parts of roasted medicated leaven, 10 parts of lindera aggregate, 15 parts of radix paeoniae alba, 12 parts of radix pseudostellariae and 3 parts of liquorice. The oral liquid provided by the invention has the effects of relieving inflammatory cell infiltration, regulating cellular immunity and humoral immunity function, restraining the activity of pepsinogen to promote proliferation and recovery thereof, strengthening barrier protection function of the mucosa, regulating gastrointestinal motility, increasing permeability of gastric mucosa, improving blood circulation of the mucosa, promoting atrophic glands to recover, and delaying or reversing progression of diseases.
Owner:李郑生

A pharmaceutical composition or health food composition for protecting gastric mucosa and its preparation method

The invention provides application of dendrobium aurantiacum Rchb. var. denneanum (Kerr)Z.H. Tsi or extract thereof to preparation of a medicine or health food for protecting gastric mucosa. The invention also provides a medicinal composition or a health food composition for protecting gastric mucosa. The medicinal composition or the health food composition is prepared from the following raw materials in part by weight: 3 to 7 parts of dendrobium aurantiacum Rchb. var. denneanum (Kerr)Z.H. Tsi, 1 to 3 parts of common bletilla pseudobulb, 3 to 7 parts of Chinese yam, 3 to 7 parts of tangerine peel, 3 to 7 parts of dandelion and 1 to 3 parts of liquorice. The invention also provides a preparation method and application of the medicinal composition. The medicine has the effect of protecting gastric mucosa, and a definite medicinal effect, and provides a new choice for clinic.
Owner:SICHUAN WANAN DENDROBIUM IND DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products